Previous close | 1.0000 |
Open | 1.1000 |
Bid | 0.6000 |
Ask | 1.7500 |
Strike | 175.00 |
Expiry date | 2023-03-17 |
Day's range | 1.1000 - 1.1000 |
Contract range | N/A |
Volume | |
Open interest | 260 |
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.